朝聚眼科(02219.HK)中期经调整纯利增加6.1%至1.45亿元 中期息每股0.1307港元
格隆汇8月29日丨朝聚眼科(02219.HK)发布公吿,2024年中期,公司收益增加6.0%至人民币734.3百万元。毛利率由2023年同期的46.6%下降至期间的45.8%。集团的纯利由2023年同期的人民币146.9百万元减少9.1%至期间的人民币133.6百万元。集团的非国际财务报吿准则经调整纯利由2023年同期的人民币136.5百万元增加6.1%至期间的人民币144.8百万元。董事会已决议宣派每股0.1307港元的中期股息(上年同期:无)。
集团经营的眼科医院数量由截至2023年6月30日的26家增加至截至2024年6月30日的31家,集团经营的视光中心由截至2023年6月30日的27家增加至截至2024年6月30日的29家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.